gene	event	source	sourceEvent	sourceUrls	studyNctId	studyTitle	studyAcronym	studyGender	countriesOfStudy	treatment	treatmentApproachesDrugClass	treatmentApproachesTherapy	applicableCancerType	applicableDoid	blacklistCancerTypes	level	direction	evidenceUrls
ALK	FUSION	CKB_EVIDENCE	fusion	http						Crizotinib			Lung Adenocarcinoma	X		A	RESPONSIVE	https
BRCA1	INACTIVATION	CKB_EVIDENCE	inact	http						DRUP			Solid Tumors	X	Hematologic cancer;2531	B	RESPONSIVE	http
ERBB2	AMPLIFICATION	CKB_EVIDENCE	amp	http						Trastuzumab			Breast Cancer	X		A	RESPONSIVE	http
ERBB2	AMPLIFICATION	CKB_EVIDENCE	amp	http						Panitumumab			Colorectal Cancer	X		B	RESISTANT	http
FGFR2	FUSION	CKB_EVIDENCE	fusion	http						Erdafitinib			Bladder Cancer	X		B	RESPONSIVE
MET	AMPLIFICATION	CKB_EVIDENCE	amp	http						DRUP			Advanced Solid Tumor	X	Hematologic cancer;2531	B	RESPONSIVE
NRAS	ACTIVATION	CKB_TRIAL	act	http	NCT1	study1	study1	male	Belgium	Cetuximab			Colorectal Cancer	X		A	RESISTANT	http